Results 1 to 10 of about 929,917 (139)

A Case of an Insufficiency Fracture of the Medial Proximal Tibia Secondary to Osteomalacia Associated with Long-Term Saccharated Ferric Oxide Administration [PDF]

open access: yesCase Reports in Orthopedics, 2017
This article presents a case of insufficiency fracture of medial proximal tibia caused by long-term administration of saccharated ferric oxide (SFO) in a 77-year-old female.
Daichi Ishimaru, Hiroshi Sumi
exaly   +8 more sources

A case of hypophosphatemia and elevated intact fibroblast growth factor 23 levels after short-term saccharated ferric oxide administration in a young woman and database analysis of adverse drug reactions in Japan [PDF]

open access: yesBone Reports
Intravenous iron replacement therapy is a common treatment for iron deficiency. Commonly used agents in this treatment include ferric carboxymaltose, ferric derisomaltose, and saccharated ferric oxide (SFO).
Yoichi Ishitsuka   +2 more
exaly   +7 more sources

Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide [PDF]

open access: yesKidney International Reports, 2018
A recent study suggested that orally dosed ferric citrate hydrate (FC) corrects renal anemia in patients on hemodialysis (HD), suggesting biological differences in effects of iron supplementation using different routes of administration.
Myles Wolf   +2 more
exaly   +6 more sources

Understanding and Managing Infusion Reactions and Hypophosphataemia With Intravenous Iron—A Nurses' Consensus Paper [PDF]

open access: yesNursing Open
Aim To provide evidence‐based guidance on practical aspects and potential safety concerns (infusion reactions and hypophosphataemia) related to the use of intravenous iron from a nursing perspective. Design A modified Delphi consensus method.
Aileen Fraser   +5 more
doaj   +3 more sources

Saccharated ferric oxide attenuates haematopoietic response induced by epoetin beta pegol in patients undergoing haemodialysis [PDF]

open access: yesBMC Nephrology, 2021
Background Decreased erythropoietin levels and impaired iron metabolism due to excessive hepcidin levels are responsible for renal anaemia in patients undergoing haemodialysis.
Takahiro Kuragano   +2 more
exaly   +5 more sources

A case of osteomalacia due to deranged mineral balance caused by saccharated ferric oxide and short-bowel syndrome [PDF]

open access: yesMedicine (United States), 2017
Saccharated ferric oxide has been shown to lead to elevation of fibroblast growth factor 23, hypophosphatemia, and, consequently, osteomalacia. Moreover, mineral imbalance is often observed in patients with short-bowel syndrome to some degree.A 62-year-old woman with short-bowel syndrome related with multiple resections of small intestines due to Crohn
Tatsuya Atsumi   +2 more
exaly   +5 more sources

Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study [PDF]

open access: yesInternational Journal of Hematology, 2022
AbstractA multicenter, randomized, open-label, phase III study was conducted to compare the efficacy and safety of intravenous ferric derisomaltose (FDI) versus saccharated ferric oxide (SFO) in Japanese patients with iron deficiency anemia associated with menorrhagia.
Hiroshi Kawabata, Yoshiaki Ota
exaly   +4 more sources

Patient with Secondary Amyloidosis Due to Crohn’s Disease on Hemodialysis Effectively Treated with Ferric Carboxymaltose Injections: A Case Report and Literature Review [PDF]

open access: yesDiseases
Background: Almost all patients undergoing dialysis develop renal anemia and receive medicines such as erythropoietin and iron preparations. However, the conventional intravenous treatment with saccharated ferric oxide (SFO) is insufficient for these ...
Masayo Ueno   +6 more
doaj   +2 more sources

Fibroblast Growth Factor 23-Related Osteomalacia Caused by the Prolonged Administration of Saccharated Ferric Oxide

open access: yesInternal Medicine, 2012
A 44-year-old woman with iron deficiency anemia was on a continuous course of intravenous saccharated ferric oxide (SFO). She came to our hospital because of right hip joint pain. She was found to have hypophosphatemia caused by impaired phosphorus resorption and her fibroblast growth factor 23 (FGF-23) levels were elevated.
Yoshiya Tanaka   +2 more
exaly   +4 more sources

Putative Role Of Fgf 23 In The Development Of Hypophosphatemia And Bone Fructures In An Anemic Patient Treated By Intravenous Saccharated Ferric Oxide

open access: yesKidney Research and Clinical Practice, 2012
A post-menopausal patient with normal kidney function was referred to our hospital because of severe lumber pain. She had been treated by initially oral, and then by intravenous iron for longer than five years for the treatment of iron deficiency anemia ...
Risa Ishida   +3 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy